
Mike Eckrote
Mike Eckrote is Senior Vice President of Strategic Solutions & CRO Channel at Advarra, focused on clinical trial technology and AI-driven innovation.
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Oct 27, 2026
S5: E3 AI Agents at Work: Connecting the Clinical Trial Ecosystem
7:41
8:08
8:14
8:26
8:36
11:27
T
7:35Travis CaudillGUEST
And Mike, I'd love to sort of hear your thoughts on it because I know you're approaching it in a slightly more technical way.

Mike EckroteGUEST
I think the points that Travis raised in terms of using it for productivity and thinking of it as a doer of tasks is probably the simplest, most rudimentary way to break it down into the most fundamental pieces, which is that in any area where you could have a human going and delegating tasks, effectively a task list with instructions, we can assign agents to then go run a battery of tasks on our behalf, right? And that is an oversimplification.

Mike EckroteGUEST
But when you think about artificial intelligence and our ability to drive automation, fundamentally, that is the way I think you can think about an agent.

Mike EckroteGUEST
When we think about agent to agent interaction, there's probably two ways I would decompose it, right? The first being, if you think about in a particular system, one agent can also communicate with other agents to orchestrate tasks.

Mike EckroteGUEST
So if to then go run a battery of tasks, but maybe there's one task in that list that they're not an expert at.

Mike EckroteGUEST
Somebody who is building these systems can start further upstream and effectively build the strategy to say, okay, to facilitate this task, you're going to have to go talk over here, right? So that's the way I think we can allow agents to speak across a outside of the boundaries of the organization.

Sophia McLeodHOST
How can these agents help all of those systems coordinate intelligence and work across organizational boundaries rather than requiring everyone to operate within the exact same platform?
Unlocking Unstructured Data with AI for Optimized Protocol Development
0:20
0:29
1:00
1:04
1:58
2:22
18:18
18:32

Danny McCarthyHOST
Mike, thanks for being here, and I'd like for you to start by talking about the technology that Advarra is deploying and the problems that it's aiming to solve.

Mike EckroteGUEST
I think at the, starting at the highest level, our product and technology leadership here at Advarra have used the, the model around build once, deploy everywhere, right? Which is if we can build a really strong foundation, which is what we call Parade, which is in simplest terms, it's a data backbone governance structure, AI strategy that will allow us to put AI in many different parts of our business and where we sit in the ecosystem as Advarra.

Mike EckroteGUEST
Now, again, not only the largest central IRB, but also the largest provider of site technologies.

Mike EckroteGUEST
We see from a data perspective, obviously there's a lot of different artifacts and data fragments in our orbit, and I think if you think about the protocols themselves as an example, there are tons of lessons to be learned and derivative insights to be gained from those trials, not only on day one when they show up via the central IRB, but the, the different permutations of, of the trial, the different evolution of those protocols and those studies over time, which often go unnoticed, right? So if you think about your coupling the baseline design with what was the actual outcome that happened in the real world, whether it be the evolution of the protocol, as I mentioned, but also what happened at the site level, right? So via the, again, the view of the world we have by being the leading site technology o- offering, we see actually how poorly designed trials impact research sites too, as well, directly.

Mike EckroteGUEST
So I think it is the, the sort of dual thread of being able to see what happens on day one, the evolution of those things over time via why trials get amended, right, the, the rationale behind those amendments, how those amendments potentially impact patient burden, how they impact site burden, how they impact recruitment velocity, and then ultimately outcomes at the sites.

Mike EckroteGUEST
That, that's where we see sort of a complete picture or, or a complete view of the world.
16 MINS LATER

Danny McCarthyHOST
What would be your advice for sponsors about how to evaluate when to use AI, what to look for in AI partners to make sure that it's actually useful for them?

Mike EckroteGUEST
The reality is nobody has been doing these cutting-edge techniques and approaches for 20 years, right? So if you want to go to an organization that's gonna be doing something on the bleeding edge, but they have 10 years of case studies and anecdotes, we're just not at that state of affairs yet.